{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:50:46Z","timestamp":1754398246703,"version":"3.28.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,23]]},"DOI":"10.7759\/cureus.72216","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:34:39Z","timestamp":1729701279000},"source":"Crossref","is-referenced-by-count":1,"title":["Reversible Dilated Cardiomyopathy in a Male Patient With Rheumatoid Arthritis: A Case Report"],"prefix":"10.7759","author":[{"given":"Cristina M","family":"Padovani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad I","family":"Fardos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Brecher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0084-1","article-title":"Dilated cardiomyopathy","volume":"5","author":"Schultheiss HP","year":"2019","unstructured":"Schultheiss HP, Fairweather D, Caforio AL, et al.. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019, 5:32. 10.1038\/s41572-019-0084-1","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.15171\/jrip.2017.04","article-title":"Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy","volume":"6","author":"Cheungpasitporn W","year":"2017","unstructured":"Cheungpasitporn W, Kopecky SL, Specks U, Bharucha K, Fervenza FC. Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. J Renal Inj Prev. 2017, 6:18-25. 10.15171\/jrip.2017.04","journal-title":"J Renal Inj Prev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147722","article-title":"Cardiomyopathies: an overview","volume":"22","author":"Ciarambino T","year":"2021","unstructured":"Ciarambino T, Menna G, Sansone G, Giordano M. Cardiomyopathies: an overview. Int J Mol Sci. 2021, 22:7722. 10.3390\/ijms22147722","journal-title":"Int J Mol Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221077422","article-title":"Reversible cardiomyopathy after rituximab treatment in a chronic lymphocytic leukemia patient","volume":"28","author":"Girkar N","year":"2022","unstructured":"Girkar N, Zaki S, Pawar S, Dhande P. Reversible cardiomyopathy after rituximab treatment in a chronic lymphocytic leukemia patient. J Oncol Pharm Pract. 2022, 28:1650-3. 10.1177\/10781552221077422","journal-title":"J Oncol Pharm Pract"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-020-00079-3","article-title":"Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy","volume":"6","author":"Kamphuis JA","year":"2020","unstructured":"Kamphuis JA, Linschoten M, Cramer MJ, Doevendans PA, Asselbergs FW, Teske AJ. Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy. Cardiooncology. 2020, 6:23. 10.1186\/s40959-020-00079-3","journal-title":"Cardiooncology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.15761\/IMC.1000129","article-title":"Drugs-related cardiomyopathy: a systematic review and pooled analysis of pathophysiology, diagnosis and clinical management","volume":"3","author":"Albakri A","year":"2019","unstructured":"Albakri A. Drugs-related cardiomyopathy: a systematic review and pooled analysis of pathophysiology, diagnosis and clinical management. Intern Med Care. 2019, 3:1-19. 10.15761\/IMC.1000129","journal-title":"Intern Med Care"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100216","article-title":"Toward a broader view of mechanisms of drug cardiotoxicity","volume":"2","author":"Mamoshina P","year":"2021","unstructured":"Mamoshina P, Rodriguez B, Bueno-Orovio A. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep Med. 2021, 2:100216. 10.1016\/j.xcrm.2021.100216","journal-title":"Cell Rep Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0656-y","article-title":"Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review","volume":"38","author":"Plantone D","year":"2018","unstructured":"Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018, 38:653-71. 10.1007\/s40261-018-0656-y","journal-title":"Clin Drug Investig"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X16666201014144022","article-title":"Cardiac complications attributed to hydroxychloroquine: a systematic review of the literature pre-COVID-19","volume":"17","author":"Fram G","year":"2021","unstructured":"Fram G, Wang DD, Malette K, et al.. Cardiac complications attributed to hydroxychloroquine: a systematic review of the literature pre-COVID-19. Curr Cardiol Rev. 2021, 17:319-27. 10.2174\/1573403X16666201014144022","journal-title":"Curr Cardiol Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2048872612471215","article-title":"Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review","volume":"2","author":"Joyce E","year":"2013","unstructured":"Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care. 2013, 2:77-83. 10.1177\/2048872612471215","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.959916","article-title":"Hydroxychloroquine-induced cardiomyopathy: a case report","volume":"4","author":"Muthukrishnan P","year":"2011","unstructured":"Muthukrishnan P, Roukoz H, Grafton G, Jessurun J, Colvin-Adams M. Hydroxychloroquine-induced cardiomyopathy: a case report. Circ Heart Fail. 2011, 4:e7-8. 10.1161\/CIRCHEARTFAILURE.110.959916","journal-title":"Circ Heart Fail"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-020-00435-x","article-title":"Myocarditis and inflammatory cardiomyopathy: current evidence and future directions","volume":"18","author":"Tsch\u00f6pe C","year":"2021","unstructured":"Tsch\u00f6pe C, Ammirati E, Bozkurt B, et al.. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol. 2021, 18:169-93. 10.1038\/s41569-020-00435-x","journal-title":"Nat Rev Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-8-1-42","article-title":"A case series of reversible acute cardiomyopathy associated with H1N1 influenza infection","volume":"8","author":"Barbandi M","year":"2012","unstructured":"Barbandi M, Cordero-Reyes A, Orrego CM, Torre-Amione G, Seethamraju H, Estep J. A case series of reversible acute cardiomyopathy associated with H1N1 influenza infection. Methodist Debakey Cardiovasc J. 2012, 8:42-5. 10.14797\/mdcj-8-1-42","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/01.crd.0000174803.68564.65","article-title":"Recurrent reversible dilated cardiomyopathy secondary to viral and streptococcal pneumonia vaccine-associated myocarditis","volume":"14","author":"Makaryus AN","year":"2006","unstructured":"Makaryus AN, Revere DJ, Steinberg B. Recurrent reversible dilated cardiomyopathy secondary to viral and streptococcal pneumonia vaccine-associated myocarditis. Cardiol Rev. 2006, 14:e1-4. 10.1097\/01.crd.0000174803.68564.65","journal-title":"Cardiol Rev"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001607160","article-title":"Cardiac toxicity during rituximab administration","volume":"45","author":"Garypidou V","year":"2004","unstructured":"Garypidou V, Perifanis V, Tziomalos K, Theodoridou S. Cardiac toxicity during rituximab administration. Leuk Lymphoma. 2004, 45:203-4. 10.1080\/10428190310001607160","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173771","article-title":"Lysosomal adaptation: how cells respond to lysosomotropic compounds","volume":"12","author":"Lu S","year":"2017","unstructured":"Lu S, Sung T, Lin N, Abraham RT, Jessen BA. Lysosomal adaptation: how cells respond to lysosomotropic compounds. PLoS One. 2017, 12:e0173771. 10.1371\/journal.pone.0173771","journal-title":"PLoS One"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2014.08.016","article-title":"Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment","volume":"30","author":"Yogasundaram H","year":"2014","unstructured":"Yogasundaram H, Putko BN, Tien J, Paterson DI, Cujec B, Ringrose J, Oudit GY. Hydroxychloroquine-induced cardiomyopathy: case report, pathophysiology, diagnosis, and treatment. Can J Cardiol. 2014, 30:1706-15. 10.1016\/j.cjca.2014.08.016","journal-title":"Can J Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2010.08.012","article-title":"The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus","volume":"10","author":"Galarza-Maldonado C","year":"2010","unstructured":"Galarza-Maldonado C, Kourilovitch MR, Molineros JE, et al.. The administration of low doses of rituximab followed by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. Autoimmun Rev. 2010, 10:108-11. 10.1016\/j.autrev.2010.08.012","journal-title":"Autoimmun Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2478\/dine-2022-0020.","article-title":"Treatment with rituximab and hydroxychloroquine in a patient with membranous nephropathy and diabetic nephropathy: a case report","volume":"3","author":"Ning X","year":"2023","unstructured":"Ning X, Xu N, Chen M, Xu J. Treatment with rituximab and hydroxychloroquine in a patient with membranous nephropathy and diabetic nephropathy: a case report. Diabet Nephropathy. 2023, 3:10-4. 10.2478\/dine-2022-0020.","journal-title":"Diabet Nephropathy"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2018-0067","article-title":"Takotsubo cardiomyopathy: a brief review","volume":"13","author":"Amin HZ","year":"2020","unstructured":"Amin HZ, Amin LZ, Pradipta A. Takotsubo cardiomyopathy: a brief review. J Med Life. 2020, 13:3-7. 10.25122\/jml-2018-0067","journal-title":"J Med Life"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-7-84","article-title":"Reverse takotsubo cardiomyopathy: two case reports and review of the literature","volume":"7","author":"Patankar GR","year":"2013","unstructured":"Patankar GR, Choi JW, Schussler JM. Reverse takotsubo cardiomyopathy: two case reports and review of the literature. J Med Case Rep. 2013, 7:84. 10.1186\/1752-1947-7-84","journal-title":"J Med Case Rep"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"72","author":"Singh S","year":"2020","unstructured":"Singh S, Fumery M, Singh AG, et al.. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2020, 72:561-76. 10.1002\/acr.23875","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.053318","article-title":"Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial","volume":"143","author":"Meyer MA","year":"2021","unstructured":"Meyer MA, Wiberg S, Grand J, et al.. Treatment effects of interleukin-6 receptor antibodies for modulating the systemic inflammatory response after out-of-hospital cardiac arrest (the IMICA trial): a double-blinded, placebo-controlled, single-center, randomized, clinical trial. Circulation. 2021, 143:1841-51. 10.1161\/CIRCULATIONAHA.120.053318","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131540","article-title":"Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging","volume":"41","author":"Kobayashi H","year":"2014","unstructured":"Kobayashi H, Kobayashi Y, Giles JT, Yoneyama K, Nakajima Y, Takei M. Tocilizumab treatment increases left ventricular ejection fraction and decreases left ventricular mass index in patients with rheumatoid arthritis without cardiac symptoms: assessed using 3.0 tesla cardiac magnetic resonance imaging. J Rheumatol. 2014, 41:1916-21. 10.3899\/jrheum.131540","journal-title":"J Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/17539447231182548","article-title":"MiR-21 and tocilizumab interactions improve COVID-19 myocarditis outcomes","volume":"17","author":"Hossein Heydari A","year":"2023","unstructured":"Hossein Heydari A, Ghaffari S, Khani Z, Heydari S, Eskandari Z, Esmaeil Heidari M. MiR-21 and tocilizumab interactions improve COVID-19 myocarditis outcomes. Ther Adv Cardiovasc Dis. 2023, 17:17539447231182548. 10.1177\/17539447231182548","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euac188","article-title":"Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis","volume":"25","author":"Kaza N","year":"2023","unstructured":"Kaza N, Htun V, Miyazawa A, et al.. Upgrading right ventricular pacemakers to biventricular pacing or conduction system pacing: a systematic review and meta-analysis. Europace. 2023, 25:1077-86. 10.1093\/europace\/euac188","journal-title":"Europace"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss AJ","year":"2002","unstructured":"Moss AJ, Zareba W, Hall WJ, et al.. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002, 346:877-83. 10.1056\/NEJMoa013474","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab249","article-title":"Cardiac resynchronization therapy via left bundle branch pacing vs. optimized biventricular pacing with adaptive algorithm in heart failure with left bundle branch block: a prospective, multi-centre, observational study","volume":"24","author":"Chen X","year":"2022","unstructured":"Chen X, Ye Y, Wang Z, et al.. Cardiac resynchronization therapy via left bundle branch pacing vs. optimized biventricular pacing with adaptive algorithm in heart failure with left bundle branch block: a prospective, multi-centre, observational study. Europace. 2022, 24:807-16. 10.1093\/europace\/euab249","journal-title":"Europace"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.07.019","article-title":"Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy","volume":"80","author":"Wang Y","year":"2022","unstructured":"Wang Y, Zhu H, Hou X, et al.. Randomized trial of left bundle branch vs biventricular pacing for cardiac resynchronization therapy. J Am Coll Cardiol. 2022, 80:1205-16. 10.1016\/j.jacc.2022.07.019","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/280736-reversible-dilated-cardiomyopathy-in-a-male-patient-with-rheumatoid-arthritis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T16:34:41Z","timestamp":1729701281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/280736-reversible-dilated-cardiomyopathy-in-a-male-patient-with-rheumatoid-arthritis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.72216","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,23]]}}}